MN42-81: A novel PD-L1-targeted immunomodulatory cisplatin prodrug for highly efficient synergistic chemo-immunotherapy of cancer
{{output}}
Cisplatin is a widely used chemotherapeutic agent, but its clinical application is limited by toxic side effects and an "immunological paradox": while chemotherapy kills tumor cells, it also induces upregulation of PD-L1, leading to immune escape. To address... ...
